A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina
McDonagh M S, Bachmann L M, Golder S, Kleijnen J, ter Riet G
Record ID 32001000013
This review aims to assess the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.
Authors' recomendations: While patients with acute coronary syndrome are very high risk in general, the generalisability of this review's findings is limited by the characteristics of the patients enrolled. For example, the mean ages of the patients enrolled in these trials (range, 59-67 years) were notably lower than the ages of patients generally seen in clinical practice. Furthermore, there may be subgroups of clinically homogeneous patients in whom these drugs are more or less effective. The results for the overall group may then underestimate or overestimate the effect for these subgroups. The trials also restricted the use of coronary interventions during the period of drug infusion, except for patients requiring emergency procedures. Because this restriction would not be in place in clinical practice, the results may not be generalisable.
Authors' methods: Systematic review
Project Status: Completed
URL for project: http://www.hta.ac.uk/1176
Year Published: 2000
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
- Angina, Unstable
- Costs and Cost Analysis
Organisation Name: NIHR Health Technology Assessment programme
Contact Address: NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name: email@example.com
Contact Email: firstname.lastname@example.org
Copyright: 2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.